A 4-week, Multi-Centre, Open-label, Rater-Blinded, Non-comparative, Phase IV Study of the Broad Clinical Benefit for Seroquel XR (Quetiapine Fumarate Extended Release) With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy.

Trial Profile

A 4-week, Multi-Centre, Open-label, Rater-Blinded, Non-comparative, Phase IV Study of the Broad Clinical Benefit for Seroquel XR (Quetiapine Fumarate Extended Release) With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2012

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Acronyms RELEASE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Mar 2012 Actual patient number (32) added as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Planned end date changed from 1 Jun 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 11 Apr 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top